Xponance LLC Increases Stake in Stryker Corporation $SYK

Xponance LLC raised its stake in shares of Stryker Corporation (NYSE:SYK) by 5.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 63,177 shares of the medical technology company’s stock after buying an additional 3,251 shares during the quarter. Xponance LLC’s holdings in Stryker were worth $22,205,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in SYK. Norges Bank purchased a new position in Stryker during the 4th quarter valued at about $1,822,272,000. Corient Private Wealth LLC boosted its stake in Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after buying an additional 1,146,998 shares in the last quarter. Alliancebernstein L.P. boosted its stake in Stryker by 13.3% in the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after buying an additional 741,542 shares in the last quarter. Strive Asset Management LLC purchased a new stake in Stryker in the third quarter worth approximately $227,389,000. Finally, Credit Agricole S A purchased a new stake in Stryker in the third quarter worth approximately $194,045,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of Stryker stock opened at $305.82 on Friday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The company has a market cap of $117.24 billion, a PE ratio of 35.40, a P/E/G ratio of 1.95 and a beta of 0.78. The business has a 50 day moving average of $316.75 and a 200 day moving average of $344.20. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities research analysts forecast that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is currently 40.74%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. BTIG Research cut their target price on Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Jefferies Financial Group reaffirmed a “buy” rating and issued a $465.00 target price on shares of Stryker in a research note on Wednesday, March 4th. Citigroup cut their target price on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Barclays cut their target price on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $330.00 target price (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average price target of $395.33.

Insider Activity at Stryker

In related news, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares in the company, valued at $3,728,937.45. This represents a 28.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 323,264 shares of company stock worth $100,659,489 over the last quarter. 4.60% of the stock is owned by corporate insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.